Arrowhead Pharmaceuticals Inc

ARWRNASDAQ · USD
58.16USD+0.70 (+1.22%)
229

Arrowhead Pharmaceuticals Inc (ARWR) Implied Volatility Current

ARWR's 30 day implied volatility is 65.51%, with an IV Rank of 55.95%. This is an average IV Rank versus the past year, meaning Arrowhead Pharmaceuticals Inc options are fairly priced and currently offer no clear edge to buyers or sellers. ARWR's 30 day historical volatility sits at 36.91%, which means implied volatility is running 28.60 points above historical volatility, as of Nov 5, 2026.

Read more

Tracking ARWR implied volatility helps you spot when Arrowhead Pharmaceuticals Inc options are historically cheap or expensive, and where the best trades are hiding. When ARWR IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ARWR implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ARWR IV rank helps you see whether ARWR's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.

Implied Volatility

IV Rank
55.95%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)65.51%

IV Rank55.95%

Historical Volatility (30d)36.91%

IV Minus HV+28.60%

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →